About entera bio ltd - ENTX
Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. It s pipeline include PTH(1-34), GLP-1 and GLP-2. The company was founded on September 30, 2009 and is headquartered in Jerusalem, Israel.
ENTX At a Glance
Entera Bio Ltd.
Kiryat Hadassah
Jerusalem, Jerusalem 9112002
| Phone | 972-2-532-7151 | Revenue | 42.00K | |
| Industry | Pharmaceuticals: Major | Net Income | -11,439,000.00 | |
| Sector | Health Technology | Employees | 22 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ENTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2,133.587 |
| Price to Book Ratio | 6.838 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -6.541 |
| Enterprise Value to Sales | 1,790.897 |
| Total Debt to Enterprise Value | 0.007 |
ENTX Efficiency
| Revenue/Employee | 1,909.091 |
| Income Per Employee | -519,954.545 |
| Receivables Turnover | 0.192 |
| Total Asset Turnover | 0.003 |
ENTX Liquidity
| Current Ratio | 6.944 |
| Quick Ratio | 6.944 |
| Cash Ratio | 6.756 |
ENTX Profitability
| Gross Margin | -71.429 |
| Operating Margin | -27,450.00 |
| Pretax Margin | -27,235.714 |
| Net Margin | -27,235.714 |
| Return on Assets | -90.131 |
| Return on Equity | -108.012 |
| Return on Total Capital | -84.166 |
| Return on Invested Capital | -106.197 |
ENTX Capital Structure
| Total Debt to Total Equity | 3.74 |
| Total Debt to Total Capital | 3.605 |
| Total Debt to Total Assets | 3.064 |
| Long-Term Debt to Equity | 1.985 |
| Long-Term Debt to Total Capital | 1.913 |